Australien - engelska - Department of Health (Therapeutic Goods Administration)

hameln pharma pty ltd - oxycodone hydrochloride, quantity: 20 mg - injection, solution - excipient ingredients: citric acid monohydrate; sodium chloride; hydrochloric acid; sodium citrate dihydrate; water for injections; sodium hydroxide - oxycodone-hameln solution for injection or infusion is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Nya Zeeland - engelska - Medsafe (Medicines Safety Authority)

mundipharma new zealand ltd - naloxone hydrochloride dihydrate 5.45mg equivalent to naloxone hydrochloride anhydrous 5 mg; oxycodone hydrochloride 10mg;   - modified release tablet - 10/5mg - active: naloxone hydrochloride dihydrate 5.45mg equivalent to naloxone hydrochloride anhydrous 5 mg oxycodone hydrochloride 10mg   excipient: ethylcellulose lactose monohydrate magnesium stearate opadry white 85f18422 povidone purified talc   stearyl alcohol - the management of moderate to severe chronic pain unresponsive to non-narcotic analgesia. the naloxone component in a fixed combination with oxycodone is indicated for the therapy and/or prophylaxis of opioid-induced constipation.

Nya Zeeland - engelska - Medsafe (Medicines Safety Authority)

mundipharma new zealand ltd - naloxone hydrochloride dihydrate 10.9mg equivalent to naloxone hydrochloride anhydrous 10 mg; oxycodone hydrochloride 20mg;   - modified release tablet - 20/10mg - active: naloxone hydrochloride dihydrate 10.9mg equivalent to naloxone hydrochloride anhydrous 10 mg oxycodone hydrochloride 20mg   excipient: ethylcellulose lactose monohydrate magnesium stearate opadry pink 85f24151 povidone purified talc   stearyl alcohol - the management of moderate to severe chronic pain unresponsive to non-narcotic analgesia. the naloxone component in a fixed combination with oxycodone is indicated for the therapy and/or prophylaxis of opioid-induced constipation.

Nya Zeeland - engelska - Medsafe (Medicines Safety Authority)

mundipharma new zealand ltd - naloxone hydrochloride dihydrate 21.8mg equivalent to naloxone hydrochloride anhydrous 20 mg; oxycodone hydrochloride 40mg;   - modified release tablet - 40/20mg - active: naloxone hydrochloride dihydrate 21.8mg equivalent to naloxone hydrochloride anhydrous 20 mg oxycodone hydrochloride 40mg   excipient: ethylcellulose lactose monohydrate magnesium stearate opadry yellow 85f32109 povidone purified talc   stearyl alcohol - the management of moderate to severe chronic pain unresponsive to non-narcotic analgesia. the naloxone component in a fixed combination with oxycodone is indicated for the therapy and/or prophylaxis of opioid-induced constipation.

Nya Zeeland - engelska - Medsafe (Medicines Safety Authority)

mundipharma new zealand ltd - naloxone hydrochloride dihydrate 2.73mg equivalent to naloxone hydrochloride anhydrous 2.5 mg; oxycodone hydrochloride 5mg;   - modified release tablet - 5/2.5mg - active: naloxone hydrochloride dihydrate 2.73mg equivalent to naloxone hydrochloride anhydrous 2.5 mg oxycodone hydrochloride 5mg   excipient: ethylcellulose hyprolose lactose monohydrate magnesium stearate opadry blue 85f30569 purified talc   stearyl alcohol - the management of moderate to severe chronic pain unresponsive to non-narcotic analgesia. the naloxone component in a fixed combination with oxycodone is indicated for the therapy and/or prophylaxis of opioid-induced constipation.

USA - engelska - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - oxycodone hydrochloride (unii: c1enj2te6c) (oxycodone - unii:cd35pmg570) - oxycodone hcl extended-release tablets are indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate in: - adults; and - opioid-tolerant pediatric patients 11 years of age and older who are already receiving and tolerate a minimum daily opioid dose of at least 20 mg oxycodone orally or its equivalent. limitations of use - because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations [see warnings and precautions (5.1)] , reserve oxycodone hcl extended-release tablets for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. - oxycodone hcl extended-release tablets are not indicated as an as-needed (prn

USA - engelska - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - oxycodone hydrochloride (unii: c1enj2te6c) (oxycodone - unii:cd35pmg570) - oxycodone hcl extended-release tablets are indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate in: - adults; and - opioid-tolerant pediatric patients 11 years of age and older who are already receiving and tolerate a minimum daily opioid dose of at least 20 mg oxycodone orally or its equivalent. limitations of use - because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations [see warnings and precautions (5.1)] , reserve oxycodone hcl extended-release tablets for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. - oxycodone hcl extended-release tablets are not indicated as an as-needed (prn

USA - engelska - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - oxycodone hydrochloride (unii: c1enj2te6c) (oxycodone - unii:cd35pmg570) - oxycodone hcl extended-release tablets are indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate in: - adults; and - opioid-tolerant pediatric patients 11 years of age and older who are already receiving and tolerate a minimum daily opioid dose of at least 20 mg oxycodone orally or its equivalent. limitations of use - because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations [see warnings and precautions (5.1)] , reserve oxycodone hcl extended-release tablets for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. - oxycodone hcl extended-release tablets are not indicated as an as-needed (prn

Malta - engelska - Medicines Authority

pinewood laboratories limited ballymacarbry, clonmel, co. tipperary, ireland - oxycodone hydrochloride - solution for infusion or injection - oxycodone hydrochloride 10 mg/ml - analgesics

Malta - engelska - Medicines Authority

pinewood laboratories limited ballymacarbry, clonmel, co. tipperary, ireland - oxycodone hydrochloride - oral solution - oxycodone hydrochloride 10 mg/ml - analgesics